Hansa Biopharma AB
HNSBF
Rank in Stocks
#14321
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Share Price
$3.29
Last synced: 2026-11-12
Market Cap
$328.20M
Change (1 day)
0.00%
Change (1 year)
13.06%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Hansa Biopharma AB (HNSBF)
Category
Healthcare
EPS for Hansa Biopharma AB (HNSBF)
EPS as of September 2026 TTM: $-0.78
According to Hansa Biopharma AB's latest financial reports, its current EPS (TTM) is $-0.78. At the end of 2025 the company had an EPS of $-0.71, an increase over its 2024 EPS of $-1.16.
EPS history for Hansa Biopharma AB from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.78 | 9.32% |
| 2025 | $-0.71 | -39.02% |
| 2024 | $-1.16 | -25.80% |
| 2023 | $-1.57 | 20.30% |
| 2022 | $-1.30 | -4.26% |
| 2021 | $-1.36 | 12.82% |
| 2020 | $-1.21 | 25.26% |
| 2019 | $-0.96 | 33.13% |
| 2018 | $-0.72 | 19.15% |
| 2017 | $-0.61 | 63.87% |
| 2016 | $-0.37 | 47.53% |
| 2015 | $-0.25 | 79.96% |
| 2014 | $-0.14 | 24.96% |
| 2013 | $-0.11 | 2.47% |
| 2012 | $-0.11 | -64.39% |
| 2011 | $-0.31 | -9.43% |
| 2010 | $-0.34 | -22.62% |
| 2009 | $-0.44 | 571.58% |
| 2008 | $-0.07 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $1.69 | -317.73% |
US
|
|
| $1.90 | -344.63% |
SE
|
|
| $6.83 | -980.52% |
FR
|
|
| $0.02 | -102.51% |
HK
|
|
| $2.81 | -462.15% |
IT
|
Questions about Hansa Biopharma AB's earnings per share (EPS)
What is Hansa Biopharma AB's earnings per share (EPS)?
Hansa Biopharma AB's earnings per share (EPS) over the last twelve months is $-0.78, as of Sep 2026.
What was Hansa Biopharma AB's earnings per share (EPS) in 2025?
In 2025, Hansa Biopharma AB's earnings per share (EPS) was $-0.71, compared with $-1.16 in 2024.
How has Hansa Biopharma AB's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Hansa Biopharma AB's earnings per share (EPS) was highest in 2025 ($-0.71) and lowest in 2023 ($-1.57).
How does Hansa Biopharma AB's earnings per share (EPS) compare with similar companies?
Hansa Biopharma AB's earnings per share (EPS) ($-0.78) is lower than that of all 5 similar companies listed above. The highest among them is Ipsen S.A., with $6.83.